Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Type 1 Diabetes Extension Study

NCT02734277 · View on ClinicalTrials.gov ↗

Study Summary

This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.

Study Locations (12)

California

  • UCSF School of Medicine — San Francisco
  • Stanford University — Stanford

Colorado

  • University of Colorado School of Medicine: Barbara Davis Center for Diabetes — Aurora

Connecticut

  • Yale University — New Haven

Georgia

  • Emory University — Atlanta

Indiana

  • Indiana University Riley Hospital for Children — Indianapolis

Iowa

  • University of Iowa Health Care Division of Pediatric Endocrinology — Iowa City

Massachusetts

  • Joslin Diabetes Center — Boston

Minnesota

  • University of Minnesota — Minneapolis

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2016-08-18
Est. Completion 2028-08

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02734277

The ClinicalTrials.gov registry entry for NCT02734277 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02734277 reports 12 study locations spanning 11 distinct geographic areas — top geographies include California, Colorado, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02734277 about?

NCT02734277 is a clinical study titled "Type 1 Diabetes Extension Study". This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how lon...

What is the current status of trial NCT02734277?

This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2016-08-18. Estimated completion is 2028-08.

What conditions does trial NCT02734277 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, T1D, T1DM. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT02734277?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02734277 being conducted?

This trial has 12 study locations across California, Colorado, Connecticut, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial